Discovery

1. Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene 11/20/2024

   Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on-site during the 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, an update on ARM's Grow Internship Program, as well as a few key takeaways from the event that sector professionals can anticipate impacting the CGTs in the next 12 months and beyond.

2. The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan 1/15/2025

   Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.

3. Gene Therapies For Spinal Cord-Related Disorders With SwanBio's CSO 9/16/2021

   Karen Kozarsky, Ph.D., Co-Founder and CSO of SwanBio explains how the company is pioneering a deep and varied pipeline of gene therapies for genetically defined neurological diseases with a focus on the spinal cord.

4. Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye 3/10/2026

   On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases.

5. Inside Prime Editing With Prime Medicine's Dr. Andrew Anzalone 6/30/2023

   What is prime editing and why is it considered a major technological advancement in gene editing?

6. The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D. 1/29/2025

   Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors.

7. The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault 7/18/2023

   Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as how the CGT sector is benefiting from RNA, AI, and synthetic biology.

8. Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D. 4/7/2026

   On episode 126 of Cell & Gene: The Podcast, Host Erin Harris welcomes Catriona Jamieson, M.D., Ph.D, Director of the UC San Diego Sanford Stem Cell Institute and Professor of Medicine at the School of Medicine.

9. Inside Sanofi's Genomic Medicine Vision with Mike Quigley, Ph.D. 9/24/2025

   On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access.

10. Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita 3/25/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics.